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Abstract
Although neurons in the adult mammalian CNS are inherently incapable of regeneration after injury, we previously showed that
exogenous delivery of pigment epithelium-derived factor (PEDF), a 50-kDa neurotrophic factor (NTF), promoted adult retinal
ganglion cell neuroprotection and axon regeneration. Here, we show that PEDF and other elements of the PEDF pathway are
highly upregulated in dorsal root ganglion neurons (DRGN) from regenerating dorsal column (DC) injury paradigms when
compared with non-regenerating DC injury models. Exogenous PEDF was neuroprotective to adult DRGN and disinhibited
neurite outgrowth, whilst overexpression of PEDF after DC injury in vivo promoted significant DC axon regeneration with
enhanced electrophysiological, sensory, and locomotor function. Our findings reveal that PEDF is a novel NTF for adult DRGN
and may represent a therapeutically useful factor to promote functional recovery after spinal cord injury.
Keywords PEDF . Spinal cord injury . Serum withdrawal . Dorsal root ganglia neurons . CNS . Axon regeneration . Neurite
outgrowth
Introduction
Injury to the central nervous system (CNS) is a considerable
cause of morbidity and mortality in modern populations. The
intrinsic inability of the CNS to repair on a cellular level leads to
poor outcomes for rehabilitation on a patient level. Neuronal
cells lost through injury are not replaced, and axons do not
regenerate; the damage acquired causes a permanent functional
deficit. Whilst spinal cord injury (SCI) presents a pertinent clin-
ical problem, no regenerative therapy is available which offers
an adequate level of functional recovery [1]. Pigment
epithelium-derived factor (PEDF) is a 50-kDa glycoprotein
and a member of the serine protease inhibitor (serpin) gene
family, with neuroprotective and angiogenic properties. PEDF
has been noted for its neuroprotective activity throughout the
CNS [2, 3]. Whilst PEDF has been shown to promote survival
and neurite outgrowth of motor neurons, evidence is limited to
in vitro studies utilising embryonic avian cultures [4]. More
recently PEDF has been shown to be both neuroprotective
and axogenic in adult retinal ganglion cells after optic nerve
crush injury [5, 6].We therefore asked the question as to wheth-
er PEDF is neuroprotective and axogenic to spinal neurons.
To test this hypothesis, we utilised dorsal root ganglion
neurons (DRGN), whose cell bodies subserve both the central
and peripheral projections, yet these neurons can regenerate
their peripheral projections but not their central projections.
These DRGN can be placed under different in vivo conditions
to create regenerating and non-regenerating models of CNS
injury [7–11]. A non-regenerating SCI can be modelled by
administering a dorsal column (DC) crush injury; DRGN
axons barely regenerate but do not extend into the DC injury
site. A peripheral regenerating paradigm can be modelled by a
sciatic nerve (SN) crush injury; axons will extend into the SN
injury site. By combining these models, pre-conditioning (p)
SN lesions, i.e. administering an SN crush lesion 7 days prior
to DC injury (pSN + DC), the central axons will extend into
and through the DC injury site as well as peripheral axons
extending into the SN lesion site [8]. Pre-conditioning is ex-
plained by upregulation of gene transcription, which enables
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DRGN to enter a ‘growth-activated state’, rendering them
capable of regenerating their axons into the DC lesion site
[10–13].
Here, we investigated DRGN survival and regeneration in
response to PEDF in the adult spinal cord, evaluating the
potential for PEDF to be of value as a regenerative therapy
in the clinical setting. We show that PEDF is activated in
regenerating models of DC injury, promotes DRGN survival
and neurite outgrowth in a serum-withdrawal model in vitro,
promotes DC axon regeneration and improved functional re-
covery in vivo, and causes the release of several Trk-
dependent neurotrophic factors (NTF) that account for some
of its survival/neurite-growth promoting effects.
Methods
Regenerating and Non-Regenerating DC Injury
Models
All surgical procedures were licenced by the UKHome Office
and ethically approved by the University of Birmingham’s
Animal and Ethical Review Board. Surgeries were carried
out in strict accordance to the guidelines of the UK Animals
Scientific Procedures Act, 1986, and the Revised European
Directive 1010/63/EU and conformed to the guidelines and
recommendation of the use of animals by the Federation of the
European Laboratory Animal Science Associations. Adult fe-
male Sprague-Dawley rats (170–220 g) (Charles River,
Margate, UK) were randomly allocated to either: (1) Sham
(control; partial laminectomy but no DC crush injury); (2)
DC crush injury (non-regenerating; partial laminectomy
followed by DC crush injury); (3) SN crush injury
(regenerating SN); and (4) pre-conditioning (p) SN crush in-
jury (pSN) 1 week prior to DC crush injury (pSN + DC).
Where specified intact animals with no surgical procedures
were also used. All lesions were administered under 5%
isoflurane-induced inhalation anaesthesia, with 1.5 l/min O2.
Pre- and post-injury analgesia was also provided.
DC crush injury was administered bilaterally at the T8 ver-
tebral level as described by us previously [9, 14]. Briefly,
calibrated watchmaker’s forceps were inserted through the
dorsal cord meninges to a depth of 1.5 mm, and a DC crush
was performed. SN crush was performed on the left SN, at the
level of the sacro-tuberous ligament, exposed at mid-thigh
level. DC injury with pre-conditioning SN injury models were
carried out as described, with SN injury preceding DC injury
by 1 week.
All in vivo experiments were performed by investigators
masked to the treatment conditions with animals randomly
assigned to treatment groups. For the microarray experiments,
four independent samples of DRG were from two pooled
DRG per experimental group from intact, DC, SN, and pSN
+ DC animals to ensure enough high-quality RNA could be
extracted (n = 8 rats/group, total for experiment = 32 rats). For
quantitative RT-PCR (qRT-PCR), RNA from four DRG/group
(n = 4 rats/group) were extracted to validate highly changed
genes in DC, SN, and pSN + DC animals and repeated on
three independent occasions (n = 12 rats/group, total for ex-
periment = 36 rats). For immunohistochemistry to determine
PEDF and PEDF-R localisation, three DRG/group were used
and repeated on three independent occasions (n = 9 rats/group,
total for experiment = 36 rats). To determine levels of PEDF
by Western blot in L4/5 DRG from intact and after DC, SN
and pSN + DC injuries, total protein extracts were prepared
from n = 3 rats/group and repeated on three independent oc-
casions (n = 9 rats/group, total for experiment = 36 rats).
To determine if PEDF overexpression by viral vector-
mediated (adeno-associated vector, serotype 8—AAV8) deliv-
ery to DRGN promotes DC axon regeneration and functional
recovery (sensory and locomotor), n = 6 rats/group were used,
repeated on three independent occasions, comprising: Sham,
DC + AAV-Null (control) and DC + AAV-PEDF (total for
experiment = 54 rats). Rat PEDF was overexpressed in
DRGN using AAV8 under the control of a CMV promoter,
referred to as AAV-PEDF from herein (AAV8-rat-SERPINF1;
cat no. AAV-291714; Vector Biolabs, Malvern, PA, USA). An
AAV8-Null vector under the control of a CMV promoter,
referred to as AAV-Null from herein (AAV8-Null; Cat no.
7077, Vector Biolabs) was used to control for AAV-PEDF
effects in vivo. 1 × 1013 viral particles of each vector in a final
volume of 5 μl of PBS was injected directly into the DRG
(intra-DRG) as described by us previously [15]. Axon regen-
eration and sensory and locomotor function were assessed at
6 weeks after SCI and treatment, as described later.
Electrophysiology (n = 6 rats/group, 3 independent repeats,
total for experiment = 54 rats) was also performed at 6 weeks
after injury and treatment, as described below.
Since AAV8-mediated overexpression is not translational
as it requires 1–2 weeks to reach maximum expression of the
transgene, we used in vivo-jetPEI, a non-viral vector, which is
just as efficient as AAV8, transducing up to 30% of DRGN
after intra-DRG injection [16]. Therefore, we determined if
PEDF overexpression by in vivo-jetPEI (referred to as PEI
from herein; Polyplus Transfection, NY, USA) promoted
functional recovery after DC injury. We used n = 6 rats/
groups comprising: Sham, DC + Vehicle, DC + PEI-Null,
and DC+PEI-PEDF, repeated on three independent occasions
(total for experiment = 72 rats) to perform electrophysiology,
tape sensing, and removal and ladder crossing tests as de-
scribed below. DC crush, preparation and injection of PEI into
L4/L5 DRG, electrophysiology, and functional tests were per-
formed as described by us previously [16]. Rats were killed at
either 28 days for qRT-PCR and enzyme-linked immunosor-
bent assay (ELISA) to determine levels of PEDF overexpres-
sion or at 6 weeks to perform electrophysiology [16].
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All other DRGN culture experiments used a total of 60 rats
(4 rats/group, run in duplicate and repeated on 3 independent
occasions). Animals were killed by exposure to rising concen-
trations of CO2.
Microarray Analysis
Groups of four rats (randomised and identity masked) com-
prising intact control, DC, SN, and pSN + DC injured animals
were treated as described above, and L4/L5 DRG pairs were
harvested from each animal and RNA extracted was extracted
using TRIzol reagent following the manufacturer’s protocol
(Invitrogen, Paisley, UK). The quality of extracted RNAwas
checked using a Bioanalyzer. The rat genome AROS™
V3.0set (Operon Biotechnologies GmbH, Cologne,
Germany) containing 26,962 long-mer probes representing
22,012 genes and 27,044 gene transcripts was used for the
microarray analysis as described by us previously [17].
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted from harvested DRG (randomised
and identity masked) at appropriate timepoints after injury
with or without treatment using TRIzol reagent following
the manufacturer’s protocol (Invitrogen). For cell culture ex-
periments, total RNA was extracted directly from wells fol-
lowing the manufacturer’s instructions. The levels of mRNA
of selected genes were determined using pre-validated rat
primer sequences from complimentary DNA prepared from
extracted mRNA, and qRT-PCR was performed using a
LightCycler PCR machine (Roche, Burgess Hill, UK) [18].
Primer sequences included PEDF-Rn00709999_m1; Akt-
Rn00583646_m1 ; p50 -Rn00550870_m1 ; SRF-
Rn01757240_m1; BDNF-Rn02537967_S1; NGF-
Rn01533872_m1; GDNF-Rn00569510_m1; Bcl2-
Rn99999125_m1 (all from Thermo Fisher Scientific,
Leicestershire, UK). Fold changes were computed using the
ΔΔCt method [18].
Pathway Analysis
Data from mRNA microarray studies of DRGN models of
injury was utilised to analyse all genes in the PEDF pathway.
Gene expression for each model was standardised as fold in-
crease compared with intact DRGN. Genes significantly al-
tered (greater or lower than 2-fold) in injury models were
represented in a schematic pathway with their corresponding
fold changes.
Immunohistochemistry
After killing animals by exposure to rising concentrations of
CO2, rats (randomised and masked) were intracardially
perfused with 4% formaldehyde (TAAB Laboratories,
Berkshire, UK) in 0.1 M phosphate-buffered saline (PBS).
DRG were removed from vertebral levels L4 and L5, post-
fixed in 4% formaldehyde and subjected to a graded series of
sucrose solutions for cryoprotection. Tissues were blocked in
OCTmounting compound (TAAB laboratories) and sectioned
at 15 μm-thick using a cryostat (Brights Instruments,
Huntingdon, UK) before being adhered to charged glass slides
(Thermo Fisher Scientific, Loughborough, UK). Slides were
kept at − 20 °C until required. Immunohistochemistry was
performed as described by us previously [14]. Briefly, slides
were washed in three changes of PBS, followed by three fur-
ther washes in PBS containing 1% (v/v) Triton X-100 (Sigma)
(PBS-T) to permeabilise cells. Sections were then blocked for
1 h at room temperature (RT) using PBS containing 0.05% (w/
v) bovine serum albumin (Sigma, Poole, UK) and 0.05%
Tween-20 (Sigma) and incubated overnight (16–18 h) at
4 °C in a humidified chamber with appropriate primary anti-
bodies: goat anti-PEDF (1:400 dilution, R&D Systems,
Oxford, UK)); mouse anti-NF200 (1:400 dilution, Sigma);
and rabbit anti-PEDF-R (1:500 dilution, R&D Systems).
Slides were washed 3× in PBS-T before incubation for 1 h
at RT with the relevant secondary antibody: Alexa488 anti-
goat; Texas Red anti-mouse; Alexa594 anti-rabbit, all diluted
at 1:400, all from Invitrogen). Slides were washed twice in
PBS-T, followed by twice in PBS. Coverslips were then
mounted using Vectashield mounting medium (containing
DAPI) (Vector Laboratories, Peterborough, UK). Negative
controls were included in each run where primary antibodies
were omitted, and these slides were used to set the background
threshold levels prior to image capture.
Protein Extraction, Western Blot, and Densitometry
Total protein,Western blot, and subsequent densitometry were
performed as described by us previously [5]. Briefly, total
protein was extracted from L4/L5 DRG from three rats
(randomised and masked; repeated on 3 independent occa-
sions, total n = 9 rats/group) after DC injury and pooled to-
gether to ensure enough protein. Forty micrograms of total
protein was resolved on 12% SDS polyacrylamide gels and
blotted onto polyvinylidene fluoride (PVDF) membranes
(Millipore, Watford, UK) and probed with relevant primary
antibodies: goat anti-PEDF (1:500 dilution, R&D Systems)
and β-actin (1:1000 dilution, Sigma; protein loading control).
Membranes were then incubated with relevant HRP-labelled
anti-goat and anti-mouse IgG secondary antibodies and bands
were detected using the enhanced chemiluminescence kit (GE
Healthcare, Buckinghamshire, UK).
For densitometry, Western blots were scanned into Adobe
Photoshop (Adobe Systems Inc., San Jose, CA, USA), and the
integrated density of bands was analysed using the built-in-
macros for gel analysis in ImageJ (NIH, USA, http://imagej.
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nih.gov/ij) by an investigator masked to the treatment
conditions [5, 11, 19]. Means ± SEM were plotted in
Microsoft Excel (Microsoft Corporation, CA, USA).
Neurotrophic Factor Enzyme-Linked Immunosorbent
Assay
The levels of brain-derived neurotrophic factor (BDNF), glial-
derived neurotrophic factor (GDNF), and nerve growth factor
(NGF) in culture were detected by ELISA using the appropri-
ate rat ELISA kits, according to the manufacturer’s instruc-
tions (Abcam, Cambridge, UK) by an investigator masked to
the treatment conditions. A rat PEDF ELISA kit was used to
detect PEDF in DRG after intra-DRG injection of AAV-PEDF
and after pSN + DC lesions, according to the manufacturer’s
instruction (Elbascience, Houston, TX, USA). ELISA was
performed on 10 μl of each sample, in duplicate, and repeated
on three independent occasions.
Adult DRGN Primary Cell Cultures
For primary DRGN cultures, adult (170–220 g) female
Sprague-Dawley rats (Charles River) were used as described
by us previously [20]. Briefly, DRG pairs (T1-L7) were re-
moved and dissociated into single cells using 0.1% collage-
nase (Sigma). DRGN were then centrifuged through a 15%
BSA gradient and the resultant cell pellet was re-suspended in
Dulbecco’s modified eagle medium (DMEM) in 8-well glass
chamber slides (BD Biosciences, Oxford, UK), pre-coated
with 100 μg/ml poly-D-lysine and 20 μg/ml laminin (both
from Sigma). Dissociated DRGN were plated at 500 cells/
well with (DMEM) containing 1% penicillin-streptomycin
(PS) (all from Invitrogen) and 30 μM 5-fluoro-2-
deoxyuridine (5-FDU, Sigma) to limit non-neuronal cell pro-
liferation [20].
In Vitro Serum Withdrawal Model
For the serum withdrawal model, DRGN were plated in
500 μl of DMEM/foetal bovine serum/penicillin-
streptomycin in 8-well chamber slides, as described by us
previously [5]. After 20–24-h incubation, the medium was
replaced with DMEM: with or without serum, and with or
without human recombinant PEDF (Peprotech, London,
UK) in the presence of 5-FDU. K252a was used at a final
concentration of 50 nM whilst Trk/A/B/C-Fc fusion proteins
were used at 5 μg/ml each [21]. Chamber slides were incubat-
ed for 120 h before being fixed in 4% formaldehyde and
subsequent immunocytochemistry, as described below. All
experiments were performed in duplicate and repeated on four
independent occasions (n = 8 wells/condition) by an investi-
gator masked to the treatment conditions.
Treatment of DRGN and ELISA to Determine NTF
Concentrations
DRGN were treated in duplicates (n = 8 wells/condition) with
or without PEDF, culture media was collected after 120 h, and
samples were assayed to determine the concentrations of NTF
using rat-specific ELISA kits, according to the manufacturer’s
protocol (R&D Systems) by an investigator masked to the
treatment conditions.
Immunocytochemistry
Immunocytochemistry was performed as described by us pre-
viously [5] by an investigator masked to the treatment condi-
tions. Briefly, cultures were fixed for 10 min using 4% form-
aldehyde, followed by ×3 washes in PBS. Non-specific stain-
ing was blocked for 10 min in PBS containing 3% BSA (w/v)
and 1% Triton X-100, followed by incubation with primary
antibody: mouse anti-βIII-tubulin (to mark DRGN soma and
neurites, diluted 1:200) for 1 h at RT, diluted in PBS with 3%
BSA and 0.5% (v/v) Tween-20. Plates were washed and incu-
bated with Alexa488-labelled anti-mouse IgG secondary anti-
body (Invitrogen, 1:400 dilution) for 1 h before mounting in
Vectamount with DAPI (Vector Laboratories).
DRGN Survival and Neurite Outgrowth
With the experimenter masked to the treatment conditions,
mean numbers of βIII-tubulin+ DRGN was counted in 9
quadrants/well and the total number of DRGN determined as
described before [20]. The number of DRGN with neurites
and the mean neurite lengths were also quantified in 9 quad-
rants/well. The longest neurite was measured using
Axiovision (Zeiss) from at least 180 DRGN/condition, whilst
total DRGN counts to assess survival were made in all wells.
Microscopy and Image Analysis
Immunostained sections were viewed under an epi-
fluorescent microscope (Axioplan 200) equipped with an
Axiocam HRc and Axiovision software (all from Zeiss,
Hertfordshire, UK). For each experiment, exposure times
were set to optimise images of control slides and adjusted to
account for background staining in negative controls (no pri-
mary antibody). An investigator masked to the treatment con-
ditions performed image capture and analysis.
To quantify fluorescence, images were captured at × 10
magnification of the entire DRG section, each taken from
the same depth through the DRG, adjusted equally in
Photoshop, and merged to a composite image using the
Photomerge tool. In ImageJ (National Institutes of Health,
USA), six areas of DRGN/section (n = 12 DRG/condition)
were selected and mean pixel counts recorded.
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Fig. 1 Microarray data showing changes in mRNA of molecules of the
PEDF pathway in non-regenerating and regenerating DRGN models.
Fold difference in mRNA extracted from DRG 10 days post-lesion after
a DC, b SN, and c pSN + DC models. Fold increase in mRNA was
normalised to the intact controls. Curved line indicates cell membrane.
Grey oval indicates nucleus. Arrows indicate promoting interaction.
Arrows with oval tips indicate inhibitory interactions. Colour chart indi-
cates fold-increase by colour heat with indicated levels of gene expression
(fold-changes compared with the intact controls)
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To measure neurite outgrowth, images of DRGN immuno-
stained for βIII-tubulin were captured for 30 randomly selected
DRGN per well. Using Axiovision Software (Carl Zeiss), the
number of DRGN with neurites and the length of the longest
neurite were recorded from aminimum of 180DRGN/condition
[20]. Image capture and subsequent analyses were performed by
an investigator masked to the treatment conditions.
Quantification of Axons
Axon regeneration in the spinal cord was quantified using
GAP43+ immunoreactivity, according to previously published
methods [22] by an investigator masked to the treatment con-
ditions. GAP43 was used since Cholera toxin B labelling did
not work in the rat [22]. Briefly, serial parasagittal sections of
cords were reconstructed by collecting all serial 50-μm-thick
sections (∼ 70–80 sections/animal; n = 18 rats/treatment), and
the numbers of intersections of GAP43+ fibres through a
dorsoventral-orientated line were counted by a masked inves-
tigator, from 4 mm rostral to 4 mm caudal to the lesion site.
Finally, axon number was calculated as a percentage of the
fibres seen 4 mm above the lesion, where the DCwas intact by
an investigator masked to the treatment conditions.
Electrophysiology
Compound action potentials (CAP) were recorded at 6 weeks
after DC injury and treatment, as described previously [16].
Briefly, the experimenter was masked to the treatment status of
the animals and the CAP amplitude was calculated between the
negative deflection after the stimulus artefact and the next peak
of the wave. CAP area was also calculated by rectifying the
CAP component (full-wave rectification) andmeasuring its area.
To confirm our recordings and that a CAP could not be record-
ed, the dorsal half of the spinal cord was transected after each
experiment between the stimulating and recording electrodes.
Functional Tests
Functional testing after DC lesion and treatment was carried out
as described previously [16, 23]. Briefly, animals (n = 18/
group) were first trained to master traversing a rope and a hor-
izontal ladder for 1 week before functional testing. Baseline
parameters were established by performing tests at 2–3 days
before injury. Animals were then tested at 2 days, 1 week,
2 weeks, 3 weeks, 4 weeks, 5 weeks, and 6 weeks after DC
injury + treatment. Experiments were performed by an observer
masked to the treatment conditions in the same order and time
of day with each test performed for three individual trials.
Horizontal Ladder Test This tests the animal’s locomotor func-
tion and is performed on a 0.9-m-long horizontal ladder with a
diameter of 15.5 cm and randomly adjusted rungs with
variable gaps of 3.5–5.0 cm. Animals were assessed traversing
the ladder, and the left and right rear paw slips were recorded
along with the total number of steps and the mean error rate as:
the number of slips/total number of steps.
Tape Removal Test (Sensory Function) The tape removal test
determines touch perception from the left hind paw. After
holding animals with both hind paws extended, the time it
took for the animal to detect and remove a piece of tape of
15 × 15 mm (Kip Hochkrepp, Bocholt, Germany) affixed to
the palm of the left hind paw was recorded and used to calcu-
late the mean sensing time.
Statistical Analysis
Statistical significance was calculated from sample means
using one-way analysis of variance (ANOVA) with post hoc
Dunnett’s method using SPSS Statistics 19 (IBM, NY, USA).
For the horizontal ladder crossing and tape removal tests,
data was analysed as described previously [16, 23] using R
package (www.r-project.org). Briefly, for the ladder crossing
test, whole time course of lesioned and Sham-treated animals
were compared using binomial generalised linear mixed
models (GLMM). Binomial GLMMs were fitted in R using
package lme4 with the glmer function. P values were then
calculated using parametric bootstrap. For the tape removal
test, linear mixed models (LMM) were calculated by model
comparison in R using the package pbkrtest, with the
Kenward-Roger method [16, 23].
Results
PEDF Signalling Pathway Is Upregulated
in Regenerating Models of DC Injury
To investigate endogenous genetic changes in non-
regenerating DC and regenerating SN and pSN + DC, micro-
array analysis of mRNA levels in DRGN was performed at
Fig. 2 Confirmation of highly changed genes in pSN + DC DRGN by
qRT-PCR and confirmation of changes in PEDF. a Confirmation of high-
ly upregulated levels of PEDF, Akt, MEK1/2, p50, SRF, BDNF, NGF,
GDNF, and Bcl2 by qRT-PCR. b Immunohistochemistry at 10 days after
DC injury and c quantification of immunopositive staining at 1, 3, 7, and
15 days post-DC injury showed high levels of PEDF immunoreactivity
(green) in regenerating SN and pSN + DC DRGN soma (red) (DAPI =
blue, cell nuclei), whilst low levels were detected in intact andDC-injured
DRGN. dWestern blot and subsequent densitometry detected high levels
of PEDF in regenerating SN and pSN + DC models, with the highest
levels of PEDF being present in pSN + DC DRG. e PEDF-R (green) was
present in DRGN and remained unchanged in intact and all injury
models. DAPI (blue) = cell nuclei. Scale bars in b and e = 25 μm. * =
P<0.05, ** = P < 0.001, ANOVA; *** = P < 0.0001, ANOVA
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10dpl. Out of the 156 genes currently known to be involved in
the PEDF pathway, 53, 49, and 53 molecules in DC, SN, and
pSN + DC models, respectively, showed any mRNA changes
compared with the intact controls with all molecules showing
significant changes (i.e. > 2-fold regulation) depicted in Fig. 1.
In non-regenerating DC models, only 3 molecules in the
PEDF pathway were upregulated > 2-fold: mRNA for
chemokines CCL2, CCL5, and CCL6 were upregulated
2.22-, 2.55-, 2.01-fold, respectively (Fig. 1a). In regenerating
SN models, 8 molecules changed > 2-fold, including the tran-
scription factor NFκB (p50, p65) which were upregulated
between 2.00- and 2.50-fold and BDNF was also upregulated
by 2.27-fold (Fig. 1b). The most marked upregulation oc-
curred in the regenerating pSN + DC model where 20 mole-
cules changed > 2-fold (Fig. 1c). These included mRNA for
PEDF, which was 4.33-fold upregulated and transcription fac-
tor NFκB (p50, p65) that was upregulated between 4.00- and
4.50-fold, respectively. Furthermore, there was a 2.55-fold
upregulation of mRNA for anti-apoptotic protein Bcl2. In ad-
dition, three NTF were highly upregulated, including glial-
derived neurotrophic factor (GDNF; 5.04-fold), nerve growth
factor (NGF; 4.32-fold) and brain-derived neurotrophic factor
(BDNF; 4.25-fold) (Fig. 1c). These results suggest that PEDF
and other pathway molecules were positively correlated with
DC axon regeneration.
PEDF mRNA and Protein Are Present in High Levels
in Regenerating SN and pSN + DC Paradigms
To validate the microarray changes observed, we performed
qRT-PCR for a selection of the most highly changed genes
and showed that the data corroborated our microarray find-
ings. These results showed significant changes in expression
of PEDF, Akt, MEK1/2, p50, SRF, BDNF, NGF, GDNF, and
Bcl2 in pSN + DCmodels compared with SN and DCmodels
(Fig. 2a). To investigate the relationship between PEDF and
an enhanced growth-activated state of CNS neurons in vivo,
PEDF and its relative levels were assessed in non-regenerating
DC and regenerating SN and pSN + DC models of injury.
PEDF immunostaining (green) was weakly positive in
DRGN (red) in the intact control and non-regenerating DC
models (Fig. 2b). However, PEDF immunostaining was high-
ly positive in DRGN in regenerating SN and pSN + DC
models (Fig. 2b). Interestingly, PEDF immunoreactivity in
DRGN from regenerating SN models was localised to the
nucleus (arrows) and DRGN somata, whilst in the
regenerating pSN + DC model, immunoreactivity was mainly
localised in DRGN somata.
Quantification of the immunoreactivity for PEDF over time
after injury in non-regenerating and regenerating models
showed that immunoreactivity reduced over time in
regenerating SN models but remained significantly elevated
(P < 0.0001, ANOVA for DC versus SN and pSN + DC at
3 days and P < 0.001 for SN versus pSN + DC at 7 days and
P < 0.0001 for SN versus pSN + DC at 15 days) in
regenerating pSN + DC models, compared with the DC and
intact controls, for a period of at least 15 days after injury (Fig.
2c). Western blot and subsequent densitometry confirmed
immunohistological changes demonstrating that SN and
pSN + DC models contained the highest levels of PEDF, with
significantly elevated levels (P < 0.001, ANOVA) present in
pSN + DC models (Fig. 2d).
For DRGN to be able to respond to changes in exogenous
PEDF, the PEDF-receptor (PEDF-R) must be present in
DRGN. Immunostaining for PEDF-R (red) in DRGN was
present in DRGN somata in the intact controls and remained
unchanged in DC, SN, or pSN + DC models (Fig. 2e). Taken
together, these results suggest that PEDF is upregulated in
regenerating SN and pSN + DC injury paradigms and remains
elevated throughout the first 15 days after injury, albeit more
so in pSN + DC models. The PEDF-R is also present in
DRGN and so are able to respond to changes in PEDF levels.
PEDF Promotes DRGN Survival in a Dose-Dependent
Manner
To investigate the role of PEDF and its involvement in DRGN
survival and neurite outgrowth, a serum-withdrawal DRGN
culture model, in the presence of 5-FDU to keep glia involve-
ment to a minimum, was used [5]. In this model, we first
confirmed that 60% DRGN death occurred at 5 days after
plating in DMEM without serum (Fig. 3a). DRGN viability
at 5 days was then quantified in this serum-withdrawal model
after DRGN culture with 0, 50, 100, 200, or 300 ng/ml PEDF
peptide and tested for its ability to promote DRGN survival
and neurite outgrowth. All doses of PEDF significantly en-
hanced DRGN viability up to a maximum observed with
100 ng/ml of PEDF, which promoted 83 ± 3% of DRGN sur-
vival (Fig. 3b). DRGN survival in the presence of 100 ng/ml
PEDF caused > 50% more survival than that observed in the
absence of PEDF (P < 0.0001) and was comparable to surviv-
al in the presence of serum (Fig. 3b). Concentrations of PEDF
above 100 ng/ml reduced DRGN survival. These results sug-
gest that PEDF rescues DRGN from death in a serum-
withdrawal model.
Fig. 3 PEDF peptide promotes DRGN survival in a serum withdrawal
model. a Approximately 40 and 60% of DRGN die after 3 and 5 days,
respectively, when cultured in the absence of serum. b Supplementation
with increasing concentrations of PEDF improved DRGN viability to
85%with 100 ng/ml PEDF after 5 days in culture, similar to that observed
in the presence of serum. cRepresentative images to showDRGN neurite
outgrowth after stimulation with 100 ng/ml PEDF, with and without
serum. d DRGN survival and e mean neurite length after treatment with
100 ng/ml PEDF, with and without serum. Scale bar in c = 100μm. *** =
P < 0.0001, ANOVA
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PEDF Is Neuritogenic for DRGN in a SerumWithdrawal
Model
DRGN grown in the presence of 100 ng/ml of PEDF and
100μg/ml CME showed enhanced levels of disinhibited
neurite outgrowth compared with those grown in DMEM
and DMEM + Serum (Fig. 3c). However, there appeared to
be no further enhancement in DRGN neurite outgrowth when
grown in the presence of DMEM + Serum + PEDF (Fig. 3c).
Quantification of the proportion of surviving DRGN with
neurites showed that only 40 ± 10% and 58 ± 8%DRGN grew
neurites when cultured in DMEMorDMEM+ Serum, respec-
tively (Fig. 3d). However, the proportion of DRGN with
neurites increased significantly (P < 0.0001) when grown in
the presence of either DMEM + PEDF reaching a maximum
of 86 ± 10%, with no further additional enhancement in the
proportion of DRGN growing neurites in the presence of
DMEM + Serum + PEDF (Fig. 3d). The mean length of the
longest neurites was also significantly greater when treated
with DMEM + PEDF (312 ± 25 μm) compared with DMEM
alone (158 ± 40 μm) or DMEM + serum (203 ± 20 μm)
(P < 0.0001) (Fig. 3e). Treatment with DMEM + Serum +
PEDF did not further potentiate neurite outgrowth when com-
pared with DMEM + PEDF (Fig. 3e). These results demon-
strate that 100 ng/ml PEDF promotes significant DRGN
neurite outgrowth.
AAV-Mediated Overexpression of PEDF Promotes DC
Axon Regeneration and Functional Recovery
Intra-DRG injection of AAV-PEDF significantly increased
PEDF mRNA levels by 8.6 ± 0.5-fold compared with only
0.1 ± 0.05-fold mRNA in DC + AAV-Null-treated rats
(Supplementary Fig. 1a). The levels of PEDF protein also in-
creased to 687 ± 29 ng/mg tissue compared with 11 ± 7 ng/mg
of tissue in the DC + AAV-Null-treated rats (Supplementary
Fig. 1b). These results demonstrated that significant titres of
PEDF mRNA and protein were induced in DRGN after intra-
DRG injection of AAV-PEDF. GAP43 immunohistochemistry
showed little or no GAP43+ regenerating fibres (green) in DC
+ AAV-Null-treated rats (Fig. 4a; inset shows high power of
boxed region). However, after treatment with AAV-PEDF, sig-
nificant numbers of GAP43+ regenerating axons were ob-
served in the caudal and rostral segments of the spinal cord
(Fig. 4b). Quantification of the number of GAP43+ fibres
showed that AAV-PEDF promoted the regeneration of 38 ±
5, 22 ± 4, 19 ± 3, and 17 ± 3% of GAP43+ fibres at 0, 2, 4,
and 6 mm rostral to the lesion site (Fig. 4c).
Electrophysiology showed that the CAP area observed in
Sham (0.71 ± 0.2 mV × ms) reduced by 94% to 0.04 ±
0.05 mV × ms in DC + AAV-Null-treated rats (Fig. 4d).
However, CAP area was significantly improved (P < 0.0001)
in the AAV-PEDF-treated groups to 64% of that observed for
the Sham controls (Fig. 4d). The mean CAP amplitude was
also significantly reduced in the DC + AAV-Null-treated
groups compared with the Sham controls (Fig. 4e).
However, significantly larger CAP amplitudes were observed
in DC + AAV-PEDF-treated rats at all stimulation intensities,
compared with those in the DC + AAV-Null groups
(P < 0.001; Fig. 4e).
The mean sensing time for the tape removal test was be-
tween 10 and 26 s in the Sham-treated controls throughout the
6-week time course (Fig. 4f). However, in the DC + AAV-
Null-treated groups, sensing time increased significantly to
77 ± 19 s at 2 days after DC injury (Fig. 4f). Sensing time
decreased over the 6-week period in DC + AAV-Null-treated
rats and remained at 36 ± 3 s at 6 weeks after DC injury. In
contrast, AAV-PEDF-treated rats showed significantly re-
duced sensing time at 2 days after DC, taking only 38 ± 4 s
to detect the tape (P < 0.001, independent sample t test) and
were not significantly different with the Sham-treated rats by
3 weeks after DC (Fig. 4f). Over the whole time course, there
was a significant reduction in the time taken to sense the
adhesive tape in the DC + AAV-PEDF-treated compared with
the DC + AAV-Null-treated animals (linear mixed model,
P < 0.001).
Over a 6-week time course, there was a significant in-
crease in the error rates during the horizontal ladder walk-
ing (generalised linear mixed model, P < 0.0011) (Fig. 4g)
in DC + AAV-Null-treated compared with DC + AAV-
PEDF-treated animals. The mean error ratio was signifi-
cantly lower in DC + AAV-PEDF compared with DC +
AAV-Null- treated animals at 2 days after injury
(P < 0.001, independent sample t test) and at 3 weeks after
DC injury (P < 0.001, independent sample t test) by which
time the error rates were similar to that of the Sham con-
trols. In the DC + AAV-Null-treated groups, error remained
for the full 6-week duration (Fig. 4g). Taken together, these
results showed that AAV-PEDF promoted DC axon regen-
eration that led to improvements in electrophysiological
and sensory and locomotor function.
Fig. 4 AAV8-mediated overexpression of PEDF promotes DC axon
regeneration and improves functional recovery. a Few if any, GAP43+
fibres were present in the caudal or rostral segments of the cord (* = lesion
site) in DC + AAV-Null-treated rats. b Numerous GAP43+ axons were
present in the caudal and rostral segments of the cord after AAV-PEDF
treatment. c Quantification of the total number of GAP43+ fibres at dif-
ferent distances caudal and rostral to the DC injury site. d CAP area and e
CAP amplitudes were significantly improved after AAV-PEDF treatment.
fMean sensing time for the tape removal and g horizontal ladder walking
tests both showed improvements in AAV-PEDF-treated rats and no sig-
nificant differences in both tests by 3 weeks when compared with the
Sham controls. Scale bars in a and b = 200 μm. * = P < 0.05, ** =
P < 0.001, *** = P < 0.0001, ANOVA; ‡‡ = P < 0.001, (independent
sample t test (DC + AAV-Null versus DC + AAV-PEDF at 2 days); # =




PEI-Mediated Overexpression of PEDF Promotes
Similar Functional Recovery as AAV
In the DC + PEI-PEDF groups, PEDFmRNAwas significant-
ly increased to 8.8 ± 0.8-fold (P < 0.0001) over that observed
for either the Sham, DC + Vehicle, or DC + PEI-Null groups
(Fig. 5a). Likewise, significant levels of PEDF protein were
extracted from DC + PEI-PEDF-treated DRG, with 698 ±
26 ng/mg compared to only 11 ± 5 and 10 ± 4 ng/mg of tissue
from DC + Vehicle and DC + PEI-Null-treated DRG, respec-
tively (Fig. 5b). These results show that PEI-delivered plas-
mids overexpressed the expression of PEDF to similar levels
in DRG as those observed with AAV8.
Electrophysiology also showed similar improvements in
the CAP area (Fig. 5c) and the CAP amplitude (Fig. 5d) in
the DC + PEI-PEDF-treated groups as those observed with
AAV-PEDF (compare with Fig. 4d, e). For example, the
CAP area in the DC + PEI-PEDF-treated groups improved
by 69% of that observed for the Sham controls, whilst the
mean CAP amplitudes were also significantly larger in the
DC + PEI-PEDF-treated rats at all stimulation intensities,
compared with those in the DC + PEI-Null groups
(P < 0.001; Fig. 5d).
PEI-mediated overexpression of PEDF also promoted sim-
ilar levels of sensory and locomotor functional recovery as
AAV. For example, in the DC + PEI-PEDF-treated rats, the
mean sensing time was 37 ± 6 s at 2 days after DC injury
(P < 0.001, independent sample t test) and sensing times were
not significantly different with the Sham-treated rats by
3 weeks after injury (Fig. 5e; P < 0.001, linear mixed model
over the whole time course). The mean error ratios for the
horizontal ladder crossing test were also significantly lower
in the DC + PEI-PEDF-treated compared with the DC + PEI-
Null-treated rats at 2 days after injury (P < 0.001, independent
sample t test), and by 3 weeks after injury, the error rates were
similar with that of the Sham controls (generalised linear
mixed model, P < 0.001) (Fig. 5f). Taken together, these re-
sults demonstrate that PEI-mediated overexpression of PEDF
was just as efficient as AAV in promoting improvements in
electrophysiological, sensory, and locomotor function after
DC injury in rats.
Addition of Exogenous PEDF Enhances NTF in DRGN
Cultures
To expound a possible mechanism for the neuroprotective and
axogenic properties of PEDF, we used dissociated DRGN
cultures, grown in the presence of 5-FDU to limit glial prolif-
eration and CME to mimic the post-injury environment of the
degenerating spinal cord to investigate secretion of NTF into
the culture medium. We determined that 100 ng/ml of PEDF
caused the secretion of 112 ± 16, 135 ± 8, and 102 ± 12 ng/ml
of BDNF, GDNF, and NGF (P < 0.0001 DMEM versus
DMEM + PEDF) into the culture medium, respectively
(Fig. 6a). No ciliary neurotrophic factor (CNTF) nor
neurotrophin-3 (NT3) were detected in the culture medium
(not shown). Reconstituting the isolated NTF in their relative
concentrations in freshly prepared DRGN cultures, grown in
the presence of CME, we observed significantly increased
DRGN survival (by > 50%; Fig. 6b), number of surviving
DRGN with neurites (i.e. neurite initiation—by 50%; Fig.
6c), and the mean neurite length (i.e. neurite elongation) from
143 ± 35 μm in DMEM alone to 312 ± 40 μm in DMEM +
BDNF + GDNF + NGF-treated cultures (Fig. 6d). The levels
of DRGN survival and neurite outgrowth were similar to that
observed with DMEM + 100 ng/ml PEDF treatment (Fig. 6b–
d). The addition of PEDF to DMEM + BDNF + GDNF +
NGF-treated DRG cultures did not further potentiate DRGN
survival (Fig. 6b) nor the number of DRGNwith neurites (Fig.
6c), but significantly increased (P < 0.0001) mean neurite
length to 449 ± 42 μm (P < 0.001), compared with DRGN
neurite outgrowth in DMEM + PEDF or DMEM + BDNF +
GDNF + NGF-treated cultures (Fig. 6d, e). These results sug-
gest that PEDF-stimulated NTF, released from DRGN cul-
tures, can promote significant DRGN neurite outgrowth and
survival, similar to PEDF-alone-treated cultures, but that the
addition of PEDF to BDNF + GDNF + NGF can further
potentiate DRGN neurite length (elongation) but not survival
nor the number of DRGN with neurites (initiation).
Trk-Dependent Neurotrophins Are Responsible
for some of the Neuroprotective and Neuritogenic
Properties of PEDF
In dissociated DRGN cultures, grown in the presence of 5-
FDU and CME, the neuroprotective effects of PEDF can be
partially abrogated by either treatment with K252a, a broad-
spectrum inhibitor of Trk-dependent neurotrophins or
TrkA/B/C-Fc fusion proteins (specific inhibitors of TrkA/B/
C [21]) (Fig. 7a). DRGN survival reduced from 85 ± 12 to 64
± 5 and 63 ± 8% in DMEM + PEDF, DMEM + PEDF +
K252a, and DMEM + TrkA/B/C-Fc fusion proteins, respec-
tively. Likewise, K252a and TrkA/B/C-Fc fusion protein treat-
ment only partially suppressed PEDF-stimulated DRGN
neurite outgrowth in terms of the number of DRGN with
Fig. 5 In vivo-jetPEI-mediated overexpression of PEDF improves simi-
lar levels of functional recovery after DC injury as AAV8. DC + PEI-
PEDF treatment overexpresses PEDF a mRNA and b protein levels sig-
nificantly compared with other treatment groups. c CAP area and d CAP
amplitudes were significantly improved after DC + PEI-PEDF treatment.
eMean sensing time for the tape removal and f horizontal ladder walking
tests both showed improvements in DC + PEI-PEDF-treated rats and no
significant differences in both tests by 3 weeks when compared with the
Sham controls. ** = P < 0.001, *** = P < 0.0001, ANOVA; ‡‡ =
P < 0.001, independent sample t test (DC + PEI-Null versus DC + PEI-
PEDF at 2 days); # = P < 0.01, generalised linear mixed models; ## =
P < 0.001, linear mixed models
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neurites (Fig. 7b) and the mean neurite length (Fig. 7c, d). For
example, the mean proportion of DRGNwith neurites reduced
from 83 ± 12 to 44 ± 8% and the mean DRGN neurite length
reduced from 310 ± 15 to 133 ± 22 μm after treatment with
K252a and TrkA/B/C-Fc fusion proteins. These results sug-
gest that DRGN survival and neurite outgrowth are directly
and indirectly affected by PEDF and that some of the effects
are Trk-dependent.
Discussion
Here, we have investigated PEDF as a novel target for pro-
moting DRGN survival and neurite outgrowth/axon regener-
ation and functional recovery in the injured spinal cord. We
utilised in vivo regenerating and non-regenerating DRGN
models and the in vitro serum-withdrawal model of DRGN
cultures, to investigate how the expression of PEDF is modu-
lated in DRGN with contrasting intrinsic growth capacities.
We showed that (1) PEDF expression in DRGN in vivo is
upregulated in regenerating (SN, pSN + DC) models; (2)
PEDF-R is expressed in DRGN in vivo; (3) PEDF promotes
significant DRGN survival and disinhibited DRGN neurite
outgrowth in a serum-withdrawal model and in the presence
of inhibitory CME; (4) intra-DRG delivery of AAV-PEDF
promoted significant DC axon regeneration and electrophysi-
ological, sensory, and locomotor function; (5) intra-DRG de-
livery of PEI-PEDF (non-viral vector) promoted similar elec-
trophysiological and functional recovery as AAV8 (viral vec-
tor delivery); (6) exposure of DRGN to PEDF in vitro causes
the release of significant titres of BDNF, GDNF, and NGF and
that these concentrations of NTF significantly enhanced
disinhibited DRGN neurite outgrowth; and (7) PEDF-
induced DRGN survival and neurite outgrowth are partially
suppressed by Trk receptor blockers.
To our knowledge, this is the first study in sensory DRGN
to demonstrate a correlation between endogenous upregula-
tion of PEDF and survival/axonal regeneration in DRGN and
the ascending DC pathway. PEDFwas previously shown to be
endogenously upregulated in activated Müller cells and con-
tributed to retinal ganglion cell (RGC) survival in several
vision-threatening pathologies [24]. We also showed that
PEDF was RGC-neuroprotective and promoted significant
RGC axon regeneration in vivo and that PEDF protein was
present in RGC, astrocytes andMuller cells in the retina [5, 6].
In contrast, this study has observed that endogenous expres-
sion of PEDF was restricted to DRGN and was absent in
satellite cells. This study demonstrated both intracellular and
extracellular activity for PEDF in regenerating DRGN
paradigms.
Results from immunohistochemistry did not identify the
presence of an extracellular PEDF-R in DRG satellite cells;
PEDF-R+ immunostaining was only present around the cell
membranes of DRGN. However, the PEDF-R has not been
fully characterised, and it is possible that PEDF acts at an
alternative, as yet unidentified receptor on satellite cells,
which is not detected by the antibody used in this and other
previous studies [25, 26]. PEDF itself, however, was first
identified as an NTF secreted by retinal pigment epithelial
cells and was originally regarded as an extracellular signalling
protein [27]. Concurrent with more recent studies, we detected
intracellular PEDF with transient PEDF+ nuclear immuno-
staining [28, 29]; the nuclear translocation motif of PEDF is
mediated by transportin-SR2 [30]. Such an uptake mechanism
may be important in mediating the neuroprotective effects of
PEDF through further interactions within the nucleus. This
would explain our observations that nuclear expression of
PEDF is only present in regenerating (SN, pSN + DC) models
and not in a non-regenerating (DC) model or in the intact
control DRGN.
Our study also demonstrated that exogenous PEDF pro-
moted DRGN survival and disinhibited DRGN neurite out-
growth in a serum-withdrawal in vitro model and is the first to
show these effects in spinal neurons of adult rats. In addition,
AAV-mediated delivery of PEDF to injured DRGN-enhanced
DC axon regeneration and improved electrophysical, sensory,
and locomotor function in treated rats. Moreover, non-viral
vector-mediated plasmid delivery through the use of in vivo-
jetPEI immediately after injury also promoted similar electro-
physiological, sensory, and locomotor functional recovery as
AAV8-mediated overexpression of PEDF. These results are in
accordance with our previous studies in other populations of
neurons, where PEDF was neuroprotective and axogenic in
RGC both in vitro and in vivo [5, 6].
Through PEDF pathway analysis, we identified an upreg-
ulation of NFκB mRNA concurrent with the upregulation of
PEDF in regenerating pSN + DC DRGN. Notably, multiple
NTF and the anti-apoptotic gene Bcl-2 were also upregulated
in this model. As a transcription factor with a nuclear
colocalisation signal, activated NFκB mediates upregulation
of NTF and anti-apoptotic genes/proteins [31]. NFκB activa-
tion is a critical step in preventing neuronal death via a number
of pathways throughout the CNS, most notably by mediating
the neuroprotective effects of PEDF in cerebellar granule neu-
rons [32]. It is therefore possible that NFκB is responsible for
Fig. 6 PEDF treatment promotes NTF secretion in DRGN cultures. a
ELISA was used to detect high levels of BDNF, GDNF, and NGF after
exposure of DRGN to 100 ng/ml PEDF in culture supernatant. b
Exposure of DRGN cultures to ELISA-detected levels of BDNF +
GDNF + NGF and PEDF + BDNF + GDNF + NGF all promotes simi-
larly high levels of DRGN survival and c the number of DRGN with
neurites. However, d mean neurite length is further potentiated by addi-
tion of PEDF compared with DMEM + PEDF-treated cultures. e
Representative images to show DRGN neurite outgrowth after treatment
with DMEM, DMEM + PEDF, DMEM + BDNF + GDNF + NGF, and
DMEM+ PEDF + BDNF +GDNF +NGF. Scale bar in e = 100 μm. ** =
P < 0.001, *** = P < 0.0001, ANOVA
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mediating some of the neuroprotective and axogenic effects of
PEDF in sensory neurons, through the upregulation of NTF
and anti-apoptotic genes/proteins. In this regard, BDNF,
GDNF, and NGF were secreted from DRGN in response to
PEDF and blockade of Trk receptors, and hence, these NTF
do not account for all of the survival and neurite outgrowth-
Fig. 7 K252a and TrkA/B/C-Fc fusion proteins partially abrogate PEDF-
stimulated DRGN survival and neurite outgrowth. K252a and TrkA/B/C-
Fc fusion proteins significantly reduce a DRGN survival b % DRGN
with neurites and the c mean neurite length. d Representative images to
show partial suppression of DRGN neurite outgrowth after treatment with
K252a and TrkA/B/C-Fc fusion proteins. Scale bar in d = 100 μm. *** =
P < 0.0001, ANOVA
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promoting effects of PEDF and suggests that PEDF has both
direct and indirect effects on DRGN.
Viral vectors, such as AAV8, are commonly used to deliver
genes into the CNS but are restricted by insert capacity and 7–
14 days delay in optimal target mRNA expression, limiting
their therapeutic effect and their translational potential for use
in acute conditions [33–37]. However, non-viral vectors such
as in vivo-jetPEI are able to transfect cells in vitro and in vivo,
are easy to prepare, stable, and safe; and give immediate ther-
apeutic benefits [38–40]. For example, melanopsin knock-
down using in vivo-jetPEI-delivered shRNA was observed
within 16 h after transduction in the eye and lasted for at least
2 months [41]. We used in vivo-jetPEI and monitored gfp
expression in DRGN after DC injury and found that in vivo-
jetPEI transduced similar proportions of large diameter
DRGN as AAV8, without invoking a non-specific innate im-
mune response [15, 16]. Given the advantages of in vivo
jetPEI over viral vectors, PEDF overexpression using such a
non-viral vector presents itself as an exciting therapeutic op-
portunity to improve functional recovery in spinal cord injury
affected patients.
In conclusion, this is the first study to demonstrate that
PEDF is an important mediator of DC axon regeneration in
the adult mammalian system. We have demonstrated that
PEDF is neuroprotective and promotes significant DRGN
neurite outgrowth, exhibiting both direct and indirect effects
on DRGN. As such, PEDF shows promise to be a potentially
novel therapy for neuroprotection and axogenesis after SCI.
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